Biohaven begins pivotal phase 3 trial of troriluzole in obsessive-compulsive disorder

New haven, conn., jan. 4, 2021 /prnewswire/ -- biohaven pharmaceutical holding company ltd. (nyse: bhvn) ("biohaven") today announced that it has commenced enrollment in a phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive...
BHVN Ratings Summary
BHVN Quant Ranking